Instalab
logoInstalab

LDL-P

Find hidden particle risk when a standard cholesterol panel looks reassuring.
4.9 (2,594 reviews)
Tested by Quest or Access Medical
Physician-reviewed results
How it works
Order from Instalab
No prescription or your own doctor's order needed
Get blood drawn
At home or at 2,000+ patient service centers
Get results
Explained with clear next steps, no medical jargon

Should you take a LDL-P test?

This test is most useful if any of these apply to you.

Told Your Cholesterol Is Fine
A normal LDL cholesterol can hide a high particle count. This shows how many plaque-forming particles you carry.
Living With Insulin Resistance
Blood sugar problems make LDL particles smaller and more numerous, which a standard cholesterol test can miss.
Taking a Statin
Statins can lower your cholesterol more than your particle count. This shows whether the particles are falling too.
Healthy but Want to Stay Ahead
A baseline gives future results a personal comparison point after diet, weight, or medication changes.

About LDL-P

Maybe you've been told your cholesterol is fine, but you also have diabetes, extra weight around your middle, or a parent who had a heart attack young. This test checks whether that "fine" answer is hiding too many LDL particles. LDL-P means low-density lipoprotein particle number. It counts the cholesterol-carrying particles most likely to enter artery walls, and in studies where the count and LDL cholesterol disagreed, heart risk often followed the count.

It's an emerging marker. Current U.S. cholesterol guidelines, including the 2026 ACC/AHA dyslipidemia guideline, don't recommend advanced lipoprotein testing for routine risk assessment, and when a particle-based measure is used to refine risk, that guideline names apoB as the preferred one. The lab method matters too. This version uses ion mobility, so compare your result with your own earlier ion mobility results, from the same lab if you can.

What This Test Counts

LDL particles are tiny spheres that carry cholesterol and other fats through your blood. They start out in the liver as larger, fat-rich particles and shrink into LDL as they give up their fat. Each LDL particle carries one copy of apolipoprotein B, so each particle is one unit of potential plaque exposure. The more of them you have, the more can get trapped in artery walls, and that buildup drives many heart attacks and ischemic strokes.

A standard lipid panel reports LDL-C. That is the amount of cholesterol inside these particles. How much cholesterol each particle carries varies more than twofold from one person to the next, so two people with the same LDL-C can have very different particle counts.

The evidence that LDL particles cause heart disease is unusually strong. Genetic studies, population studies, and drug trials covering more than 2 million people and more than 150,000 heart attacks, strokes, and related events agree on the main point: higher and longer exposure causes more disease, and lowering exposure lowers risk. Most of that work measured LDL cholesterol or apoB rather than ion mobility LDL-P, but those measures usually move together. Across the trial and genetic evidence, risk keeps falling as exposure falls, with no clear point where benefit stops.

Why the Lab Method Changes Your Number

Labs count LDL particles in more than one way. NMR stands for nuclear magnetic resonance. NMR spectroscopy estimates particle numbers from a magnetic signal given off by the fats inside them, so it infers the count rather than tallying particles. Ion mobility first spins the sample to remove other blood proteins, then sorts the particles by size as they drift through an electric field and counts them directly, one size band at a time.

Both methods report in the same unit, but they aren't standardized against each other and don't produce interchangeable numbers for the same sample. Cutoffs from NMR studies don't transfer directly to an ion mobility result, and switching methods or labs between tests can make your number jump with no change in your arteries. Few studies have compared ion mobility head to head with standard and other advanced lipid measures. The biology is the same whichever method you use. The scale isn't.

Heart Attack and Plaque Risk

Across many studies, a higher particle count goes with more heart disease, and in several the count beat LDL cholesterol at predicting who would develop it. The classic discordance studies used NMR. Ion mobility has some direct outcome data too: in JUPITER and Malmo, higher ion mobility LDL particle measures predicted cardiovascular events. The ion mobility evidence base is smaller, so use the NMR studies for the direction and strength of the link, not for exact numeric cutoffs.

Who Was StudiedWhat Was ComparedWhat They Found
About 3,000 adults in the Framingham Offspring StudyParticle count versus LDL cholesterol and non-HDL cholesterol for predicting future heart diseaseThe particle count was the stronger predictor, and a low count picked out people at lower risk better than a low LDL cholesterol did
About 6,800 adults from four ethnic groups in the Multi-Ethnic Study of AtherosclerosisPeople whose particle count and LDL cholesterol pointed in different directionsSigns of artery disease and heart events followed the particle count, not the cholesterol
284 adults at intermediate heart risk with no symptomsHighest third versus lowest third of particle countAbout 3.7 times as likely to have calcium in their heart arteries

Sources: Cromwell et al. (Framingham Offspring Study); Otvos et al. (Multi-Ethnic Study of Atherosclerosis); Prado et al.; Mora et al. (JUPITER); Melander et al.

What this means for you: a high count is a reason to treat your heart risk as higher than your standard panel suggests, especially if a coronary calcium scan or your family history points the same way. A low count is more reassuring than a low LDL cholesterol alone, because it means fewer LDL particles are available to build plaque.

The evidence has limits. A 2009 systematic review found the link between particle count and heart disease consistent, but judged it too early to recommend routine particle testing for everyone, because the added value over standard risk factors hadn't been clearly shown across whole populations. A later analysis in the same multi-ethnic cohort found that particle measures only slightly improved how people were sorted into risk groups, didn't significantly improve overall prediction, and lost strength once standard lipids were accounted for. Across studies, LDL-P predicts risk about as well as apoB or non-HDL cholesterol, not clearly better. The count is most useful in the specific situations below.

When Your Cholesterol and Particle Count Disagree

Disagreement between the particle count and LDL cholesterol is common, and it follows a pattern. It shows up most in people with insulin resistance, metabolic syndrome, type 2 diabetes, or high triglycerides. In those conditions the liver turns out smaller particles that each carry less cholesterol, so LDL cholesterol can look normal while the count runs high. In a large study of women followed for coronary events, LDL cholesterol alone underestimated risk for some women and overestimated it for others whenever it disagreed with particle-based measures.

Statins complicate this further. They tend to lower LDL cholesterol more than they lower the particle count, so you can hit your cholesterol goal on a statin and still carry a lot of particles.

What this means for you: if you have any of those metabolic features, or you're on a statin, a normal LDL cholesterol doesn't settle the question. This is where a particle count adds the most.

How It Compares With ApoB

An apoB test measures apolipoprotein B directly. Every plaque-forming lipoprotein particle carries one copy of this protein. That means apoB counts LDL plus the larger fat-rich remnants and Lp(a). This LDL-P result is narrower: it reports the LDL particle count by ion mobility. LDL usually makes up most of the apoB-containing particle pool, so LDL-P and apoB often agree, and a review of 25 clinical studies found that apoB and NMR-measured LDL-P carried very similar risk information, both better than LDL cholesterol.

When they disagree, apoB seems to be the better guide. In about 41,000 UK Biobank participants, risk followed apoB, and the extra risk was visible with as little as a 2% gap between the two. Lab expert groups favor apoB as the main particle test because it's cheaper, easier to get, and better standardized between labs, and the 2026 U.S. dyslipidemia guideline names apoB, not LDL-P, as the preferred particle measure. A split between them also hints at the cause: one pattern goes with insulin resistance and small LDL particles, the other with high Lp(a) or remnant particles.

What this means for you: LDL-P is most informative alongside apoB. If both are high, the message is clear. If they split, lean on apoB for risk and use the split to decide what to check next.

Particle Size Versus Particle Count

Your report may also show a small LDL particle count, a peak size, or a size pattern. Small, dense LDL has been tied to heart disease in many studies. In a pooled analysis of 21 studies with about 30,600 people, having high levels of small dense LDL carried about 36% more risk of coronary heart disease.

That can sound like size is the problem, but when researchers count all the particles first and then ask what size adds, the answer is very little. In about 207,000 UK Biobank participants, the number of apoB-carrying particles drove coronary risk, and particle type and size had minimal extra effect. The two findings fit together once you remember that small particles each hold less cholesterol. A person with mostly small LDL usually has more particles at the same cholesterol level, so small size works mainly as a sign of a high count, and the count is what you want to lower.

Why a Single Reading Can Fool You

Several things can push one result away from your usual level without any change in your long-term risk.

  • Method or lab changes: NMR and ion mobility give different numbers for the same sample, and so can two labs using similar methods. Comparing across them is the most common way people misread a change.
  • A recent heart attack or major illness: in heart attack patients, LDL particle concentration was lower 24 hours after the event, partly from newly started statins and partly from the event itself. Wait until you've recovered before testing for a baseline.
  • A medication that just started or changed: a draw taken before a new cholesterol drug has settled shows a number still in motion. Retest once you've been on a steady dose for a few months.
  • Eating before the draw: a recent meal changes triglycerides and the large fat-rich particles more than it changes LDL measures, but keep your fasting status the same every time so your results stay comparable.
  • High Lp(a) or remnant particles: LDL-P is not a total apoB particle count, so apoB can look worse than LDL-P when non-LDL apoB particles matter. That is biology, not a lab error.

Uncommon lab factors can affect a result. If the number is surprising or doesn't fit apoB, repeat it before acting on it.

Tracking Your Trend

An LDL particle count is most useful as a series. One reading shows where you are, and a series shows whether what you're doing is working while evening out the noise in any single draw. Because ion mobility cutoffs are less standardized across labs than LDL-C or apoB, your own history is the most reliable yardstick.

Get a baseline. If you start a statin, ezetimibe, a PCSK9 inhibitor, or a serious change in diet or weight, retest in about 3 months, then at least once a year. Use the same lab and the same ion mobility method every time, with the same fasting status.

Trials have measured particle counts falling with PCSK9 inhibitors, statin-based therapy, ezetimibe/simvastatin, niacin, and CETP inhibitors. Most particle trials used NMR or other methods rather than ion mobility. Exercise trials more consistently improve triglycerides and small LDL subfractions than total LDL-P, so a falling total count with training is useful personal data rather than a guaranteed trial result.

What to Do With an Unexpected Result

A high count calls for confirmation and context before treatment. Retest on the same method, and pair it with apoB, a standard lipid panel, and Lp(a) if you've never measured it. Lp(a) is largely inherited and usually needs only one test. Then read the combination.

  • High count, normal LDL cholesterol: check fasting insulin, HbA1c, and triglycerides, because this pattern usually comes with insulin resistance. Fixing the metabolic problem is part of lowering the count.
  • High count and high apoB: this is the clearest sign of too many plaque-forming particles. A coronary calcium scan can show whether plaque has already formed, and it's worth talking with a prescriber about lipid-lowering medication.
  • High count on a statin with LDL cholesterol at goal: your particles haven't fallen as far as your cholesterol. A higher statin dose or an add-on drug is a decision to make with a prescriber.
  • Count and apoB disagree: use apoB as the main guide to risk. Check Lp(a) and remnant-particle clues if apoB is higher, and check insulin resistance markers if LDL-P is higher.

If your count stays high despite treatment, if heart disease came early in your family, or if your LDL cholesterol is very high, a preventive cardiologist or lipid specialist is worth seeing. Don't wait for symptoms. Plaque builds silently for decades, and the evidence says lowering the particle burden earlier and for longer gives the largest benefit.

What Moves This Biomarker

Evidence-backed interventions that affect your LDL-P level

↓ Decrease
Take a PCSK9 inhibitor, such as evolocumab or alirocumab
These injections lower your particle count substantially by helping the liver clear LDL particles from the blood. In randomized trials and particle studies, evolocumab lowered LDL and related particle measures, with large drops in smaller particles in familial dysbetalipoproteinemia and broad reductions in plaque-forming lipoproteins in hyperlipidemia and diabetes studies. These studies did not all use ion mobility, so the size of the drop on your test may differ.
MedicationStrong Evidence
↓ Decrease
Take a statin, such as atorvastatin or rosuvastatin
Statins are first-line drugs for lowering plaque-forming particles, and large randomized trials show that lowering LDL exposure cuts heart attacks and strokes. Particle studies show a catch: statins often lower LDL cholesterol more than they lower LDL particle count, so your cholesterol can reach its goal while your count stays relatively high. This test can catch that gap.
MedicationStrong Evidence
↓ Decrease
Take a CETP inhibitor, such as evacetrapib, studied as an experimental drug
Drugs in this class can cut your particle count sharply. CETP is a protein that shuttles cholesterol between particles. In a randomized trial of 393 people with mildly high cholesterol, evacetrapib alone or with a statin roughly halved the total LDL particle count and nearly eliminated small LDL particles. This shows what the class can do to the number; it doesn't describe a drug you can fill at a pharmacy, and clinical outcome results have differed across drugs in this class.
MedicationStrong Evidence
↓ Decrease
Add ezetimibe to statin therapy
Ezetimibe blocks cholesterol absorption in the gut and is commonly added when statin therapy has not lowered plaque-forming particles far enough. Randomized studies of ezetimibe/simvastatin found lower LDL particle number by NMR and lower apoB, so a lower ion mobility LDL-P would be expected, though the exact change is method-specific.
MedicationModerate Evidence
↓ Decrease
Take extended-release niacin
Niacin can lower the number of plaque-forming particles by slowing how fast the liver makes them. In a small randomized trial of statin-treated men with type 2 diabetes, it lowered apolipoprotein B in LDL and larger fat-rich particles. That trial measured the protein rather than ion mobility LDL-P, so the effect on this test is inferred. Modern outcome trials have not shown clear added heart benefit when niacin is added to well-treated statin therapy, so this is not a first-line way to lower the count.
MedicationModerate Evidence
↓ Decrease
Combine several healthy habits: never smoking, regular physical activity, a high-quality diet, moderate alcohol, and a normal body weight
People who kept up these habits had fewer total and small LDL particles, and larger LDL particles, than people who didn't. This comes from a study of about 2,000 middle-aged and older adults that compared people at one point in time, so it shows an association rather than proof that adopting the habits will lower your number. The particles were measured by a different lab method than ion mobility.
LifestyleModest Evidence

Frequently Asked Questions

References

36 studies
  1. M. Caulfield, Shuguang Li, Gloria Lee, P. Blanche, W. Salameh, W. Benner, R. Reitz, R. KraussClinical Chemistry2008
  2. O. Melander, D. Shiffman, M. Caulfield, J. Louie, C. Rowland, J. Devlin, R. KraussJournal of the American College of Cardiology2015
  3. J. Otvos, S. Mora, I. Shalaurova, P. Greenland, R. Mackey, D. GoffJournal of Clinical Lipidology2011
  4. S. Ip, a. Lichtenstein, M. Chung, J. Lau, E. BalkAnnals of Internal Medicine2009

LDL-P Testing Options

$55

See the particle-level heart risk hiding behind a normal cholesterol result.

Includes 6 biomarkers:
LDL-PSmall LDL-PMedium LDL-PLarge HDL-PLDL Peak Size
$149

See whether your particle count is driving heart risk even when your cholesterol number looks fine.

13 biomarkers
FSA/HSA eligible
No Rx needed
HIPAA compliant